Pharmaceutical Drugs Industry Overview

The pharmacovigilance market consists of sales of pharmacovigilance services by entities (organizations, sole traders, and partnerships) that collect, assess, and distribute drug safety and efficiency data. Pharmacovigilance is the science and practice of monitoring approved pharmaceuticals and experimental products prior to their approval for use in order to discover, evaluate, assess, and avoid adverse drug and vaccination effects and problems. The main types of pharmacovigilance are spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining. Spontaneous reporting is by nature a passive approach to pharmacovigilance relying entirely on the motivation of individuals to report suspected adverse drug reactions to local or national pharmacovigilance centers. The different process flows include case data management, signal detection, and risk management system. The various services providers are in-house and contract to outsource and involve several clinical trial phases such as preclinical, phase I, phase II, phase II, and phase IV. These services are used by several end-users including hospitals pharmaceutical companies and others. The global pharmacovigilance market is expected to grow from $5.71 billion in 2021 to $6.64 billion in 2022 at a compound annual growth rate (CAGR) of 16.2%. The global pharmacovigilance market is expected to reach $10.57 billion in 2026 at a CAGR of 12.3%. The growing incidences of adverse drug reactions are expected to propel the growth of the pharmacovigilance market going forward. An adverse drug reaction is defined as a harmful, unpleasant, or dangerous reaction resulting from the use of any medicinal product. Pharmacovigilance personnel is primarily responsible for monitoring adverse drug reactions (ADRs) in order to ensure safe drug usage and ensure drug safety prior to approval for public use. For instance, according to United Nations Office on Drugs and Crime (UNODC) World Drug Report published in 2021, approximately 36 million persons worldwide suffered from drug use disorders in 2020, out of 275 million drug users. Therefore, the growing incidence of adverse drug reactions is promoting the growth of the pharmacovigilance market. Technological advancements have emerged as a key trend gaining popularity in the pharmacovigilance market. Many companies operating in the pharmacovigilance sector are adopting advanced technological solutions such as Artificial intelligence (AI) to reduce cycle time, enriched quality and accuracy, scalable and futuristic solutions, improved productivity, and better compliance. For instance, in December 2019, UCB, a Belgium-based biopharmaceutical company, and Accenture, an Ireland-based professional services company collaborated to develop a patient safety solution based on Accenture's INTIENT Pharmacovigilance technology platform. This solution will use real-time artificial intelligence (AI), robotic process automation, and machine learning automation in the data management process, from acquiring patient information and inputs to regulatory reporting. In January 2020, Ergomed Plc., a UK-based pharmaceutical industry service provider acquired Ashfield Pharmacovigilance Inc. for $10 million. With this acquisition, Ergomed Plc will strengthen Ergomed CRO business in the US market and will become a global leader in pharmaceutical services specialists. Ashfield Pharmacovigilance Inc. is a US-based company that provides pharmacovigilance services. Major players in the pharmacovigilance market are Accenture, Cognizant, Labcorp Drug Development, IQVIA, IQVIA, Parexel International Corporation, BioClinica Inc., Clinquest Inc., ITClinical, TAKE Solutions Limited, United BioSource LLC, Wipro Limited, Bristol-Myers Squibb Company, Linical Americas, iMEDGlobal, Boehringer Ingelheim International GmbH, Novartis AG, Ecron Acunova Limited, and Sanofi. North America was the largest region in the pharmacovigilance market in 2021. Asia Pacific is expected to be the fastest growing region in the global pharmacovigilance market during the forecast period. The regions covered in the global pharmacovigilance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmacovigilance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global pharmacovigilance market is segmented - 1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining 2) By Service Provider: In-House, Contract Outsourcing 3) By Process Flow: Case Data Management, Signal Detection, Risk Management System 4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV 5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

The pulmonary arterial hypertension market consists of sales of drugs by entities (organizations, sole proprietors, partnerships) that are used in the treatment of pulmonary arterial hypertension disease, which is a rare progressive disorder characterized by high blood pressure in the arteries of lungs. During this medical condition walls of the pulmonary arteries thicken and stiffen, making it difficult for the blood to flow through the lungs. The pulmonary arterial hypertension drugs relax the muscles in the wall of the blood vessels or increase the blood flow through the lungs or reverse the effect of the substance in the walls of blood vessels, which caused them to narrow. The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/ subcutaneous. inhalational modes and distributed through retail and online channels. The global pulmonary arterial hypertension market is expected to grow from $6.59 billion in 2021 to $7.04 billion in 2022 at a compound annual growth rate (CAGR) of 6.85%. The pulmonary arterial hypertension market is expected to reach $9.65 billion in 2026 at a CAGR of 8.22%. The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and related hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published in National Organization for Rare Disorders, Inc., the new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500-1000 new cases each year, and Europe is expected to have similar incidence rates. Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drugs sector are focusing on developing new medicines to improvise and cure the diseases. In March 2019, Sandoz, a Switzerland-based company specializing in high-quality affordable medications announced the first fully substitutable AP-rated generic version of Remodulin treprostinil injection in the USA sold by United Therapeutics Corporation. Treprostinil Injection is used to reduce the symptoms of Pulmonary Arterial Hypertension and has the same active ingredient, strengths, dose form, and inactive ingredients as Remodulin® (treprostinil), and it is provided to patients and clinicians with the same level of service and support but at a lower cost. In September 2021, Merck Group a German-based multinational science and technology company that specializes in healthcare and life sciences solutions acquired Acceleron Pharma for $11 billion. Through this acquisition, Merck will obtain ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication and also puts the company at the forefront of rare disease-focused companies. Acceleron Pharma is a US-based company committed to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions such as pulmonary arterial hypertension. Major players in the pulmonary arterial hypertension market are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc, Natco Pharma Ltd, Zydus Pharmaceutical USA, and Liquidia Technologies Inc. North America was the largest region in the pulmonary arterial hypertension market in 2021. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global pulmonary arterial hypertension market is segmented - 1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators 2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational 3) By Distribution channel: Retail, Online

The botanical supplement market consists of sales of botanical supplements by entities (organizations, sole traders, and partnerships) that manufacture and sell a wide range of health products made from plants, including their oils, roots, seeds, berries, and flowers. A botanical is a plant or plant part that has medical or therapeutic characteristics, as well as flavour and aroma. Botanical supplements are made from botanicals that are used to maintain and improve health. The main volumetric video components include hardware, software, and services. Volumetric video hardware is used to digitise a three-dimensional space by positioning various cameras around a target.such as cameras and processing units is used to capture things that can be digitised and repositioned on the mobile, web, or virtual worlds and viewed in 3D. The different volumetric video content delivery modes include projectors, AR/VR head-mounted displays (HMD), smartphones, and volumetric displays. The various applications of volumetric video include sports and entertainment, medical, signage and advertising, and education and training.  The global botanical supplements market size is expected to grow from $48.01 billion in 2021 to $51.48 billion in 2022 at a compound annual growth rate (CAGR) of 7.24%. The growth in the market is mainly due to the companies' rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global botanical supplement market size is expected to reach $69.33 billion in 2026 at a CAGR of 7.72%. The increasing number of health-conscious consumers is significantly driving the growth of the botanical supplements market. Botanical supplements have numerous health benefits, have digestive properties, and are chemical free. According to the International Food Information Council's (IFIC) 2020 food and health survey, Americans have a strong interest in becoming more health-conscious, with 43% following a specific diet or eating pattern in 2020, up 38% from 2019. Also, 54% of all consumers cared more about the healthfulness of their food and beverage choices in 2020 than they did in 2010. Hence, the increasing number of health-conscious people is expected to propel the growth of the botanical supplements market in the forecast period. Strategic collaborations between companies are a key trend gaining popularity in the botanical supplement market. Companies manufacturing botanical supplements are undergoing partnerships and collaborations to develop new technologies and products. For instance, in July 2021, the American Herbal Pharmacopoeia (AHP), the ABC-AHP-NCNPR Botanical Adulterants Prevention Program (BAPP), and the American Botanical Council (ABC) are all involved in the partnership that shares access to resources on botanical ingredients. The partnership is aimed at helping the dietary supplement sector deal with adulteration by providing access to information and control tools. Also in 2019, the United Natural Products Alliance (UNPA) and the University of Arkansas for Medical Sciences entered into a Memorandum of Understanding (MOU) partnership to advance projects and botanical identification programs.  In July 2021, Bluebird Botanic, a natural supplement company that specialises in hemp and CBD oil based in the United States, acquired Precision Botanicals for an undisclosed amount. The deal enables Bluebird access to Precision's hemp cultivation and extraction facility in Oregon as well as its core science, technology, and data-driven consumer insights. Precision Botanicals is a US-based botanical supplement company and is a producer of cannabidiol products. Major players in the botanical supplements market are The Himalaya Drug Company, Blackmores Limited, Glanbia Nutritionals, Gaia Herbs LLC, Amway Corporation, Ricola AG, Procter and Gamble, Bio-Botanica Inc, Herbalife Nutrition, The Nature's Bounty Co., Archer Daniels Midland Company (ADM), MMJ International Holdings, Pharmavite LLC, and Prinova Group North America was the largest region in the botanical supplements market in 2021. Asia-Pacific is expected to be the fastest-growing region in the global botanical supplements market during the forecast period. The regions covered in the global botanical supplements market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the botanical supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global botanical supplements market is segmented - 1) By Source: Herbs, Leaves, Spices, Flowers, Others 2) By Form: Powder, Liquid, Tablets, Capsules, Gummies, Others 3) By Application: Energy and Weight Management, Bone and Joint Health, Gastrointestinal Health, Immunity, Cardiac Health, Diabetes, Anti-Cancer, Others 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The herbal supplements market consists of sales of herbal supplements by entities (organizations, sole traders, and partnerships) that refer to supplements derived from plants that are used for improving health conditions. Herbal supplements that are generally extracted from natural raw materials such as moringa, echinacea, cohosh, turmeric, ginger, flaxseeds, and other herbs are sold in the form of capsules, tablets, powder, or liquid having certain medicinal properties.  The main forms of herbal supplements are tablets, capsules, liquids, powders, granules, and soft gels. Herbal tablet supplements are derived from plants, oils, roots, seeds, berries, or flowers and are sold in tablet form to maintain health or treat health problems. Herbal supplements are sourced from leaves, fruits, roots, vegetables, and barks. The different applications of herbal supplements include food and beverages, pharmaceuticals, and personal care products, which are distributed through store-based and non-store-based mediums.  The global herbal supplements market size is expected to grow from $9.42 billion in 2021 to $10.10 billion in 2022 at a compound annual growth rate (CAGR) of 7.27%. The growth in the market is mainly due to the companies' resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global herbal supplement market size is expected to reach $13.32 billion in 2026 at a CAGR of 7.16%. The increasing number of health-conscious consumers is significantly driving the growth of the herbal supplements market. Herbal supplements have numerous health benefits and are chemical-free. They are used to supplement diets and cure common ailments. According to the International Food Information Council's (IFIC) 2020 food and health survey, Americans have a strong interest in becoming more health-conscious, with 43% following a specific diet or eating pattern in 2020, up 38% from 2019. Also, 54% of all consumers cared more about the healthfulness of their food and beverage choices in 2020 than they did in 2010. Hence, the increasing number of health-conscious people is expected to propel the growth of the herbal supplements market in the forecast period. Companies in the herbal supplements market are increasing their investment in research and development. This trend is positively impacting the market. For example, in February 2022, US-based health, beauty, and home care products company, Amway, collaborated with Indian technological institute, IIT Bombay, to speed up its research in the fields of botanicals, nutraceuticals, and herbal supplements. With this partnership, a team of in-house Amway researchers and IIT Bombay will collaboratively work to innovate in the different areas and to improve the nutrition and herbal range of products and ingredients of Amway. In July 2021, GenTech Holdings, a US-based company engaged in providing functional foods, acquired a 75% controlling interest in Nature Spoon LLC (Nature Soothie). With this acquisition, GenTech Holdings expanded its geographic presence and product portfolio. The deal also gives GenTech Holdings access to a new segment of consumers. Nature Soothie is a US-based company involved in producing Nature Soothie® branded herbal supplement lollipops for children. Major players in the herbal supplement market are Ancient Greenfields PVT LTD, Archer Daniels Midland Company, Arizona Natural Products, Bio-Botanica Inc., Blackmores, Herbalife International of America, Inc., Ricola, Solgar, Inc., Jarrow Formulas, Inc., Glanbia PLC, Gaia Herbs, NBTY, Inc., Nature's Bounty, NaturaLife Asia Co., Ltd., Nutraceutical International Corporation, herbochem, Swanson Health Products, Third Coast Herb Co., Now Health Group, Herbal Africa, Sunfood Nutraceuticals, Wonder Labs, Wellness Origin Indy, ABCO Laboratories, Inc., Dabur, Weleda, Schwabe, Kunming Pharma, Taiji, DSM, and Rainbow Light Nutritional Systems. In 2021, North America will be the largest region in the herbal supplement market. Asia-Pacific is expected to be the fastest-growing region in the global herbal supplement market during the forecast period. The regions covered in the global herbal supplements market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the herbal supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global herbal supplements market is segmented - 1) By Form: Tablets, Capsules, Liquid, Powder and Granules, Soft Gels 2) By Source: Leaves, Fruits, Roots, Vegetables, Barks 3) By Application: Food and Beverages, Pharmaceuticals, Personal Care 4) By Distribution: Store Based, Non-Store Based

The hyperphosphatemia treatment market consists of sales of hyperphosphatemia products by entities (organization, partnerships, and sole traders), which are used to restrict phosphate intake and the administration of phosphate-binding antacids like carbonate. Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood, it can cause chronic renal disorder, hypoparathyroidism, and metabolic or respiratory acidosis. The main products in the hyperphosphatemia treatment market are sevelamer, calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and others. The sevelamer market consists of sales of sevelamer products by entities (organization, partnerships, and sole traders) that refers to phosphate binding medication used for treatment of hyperphosphatemia in patients with chronic and kidney diseases. The hyperphosphatemia treatment are distributed through hospital pharmacies, retail pharmacies, and online stores. The global hyperphosphatemia treatment market size is expected to grow from $3.22 billion in 2021 to $3.57 billion in 2022 at a compound annual growth rate (CAGR) of 10.7%. The global hyperphosphatemia treatment market size is expected to grow to $5.5 billion in 2026 at a CAGR of 11.5%. Increasing chronic diseases among patients is driving the growth of the hyperphosphatemia treatment market. Chronic diseases are non-communicable and require long-term care. A vast majority of chronic diseases can be categorized as cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer. According to the world health organization (WHO), chronic disease prevalence is predicted to increase by 57% by the year 2020. According to the United States Renal Data System they estimated that there are more than 300,000 patients with end-stage renal disease in the United States. There had been an increase in Hyperphosphatemia among patients with end-stage renal disease (ESRD), thus contributing to increase in demand for hyperphosphatemia treatment or drugs. The increasing research & development activities are a key trend in the hyperphosphatemia treatment market. The company in hyperphosphatemia treatment are focusing on R&D activities for the development of innovative therapies for the treatment of renal diseases and related chronic conditions. For instance, in May 2021, Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company raised $60 million in a Series B round to accelerate its development activities of innovative drugs and solutions for the treatment of renal diseases including hyperphosphatemia. In December 2020, Unicycive a US-based company that develops novel treatments across multiple therapeutic areas acquired Renazorb, for an undisclosed amount. This acquisition will helps Renazorb rapidly develop an alternate treatment for hyperphosphatemia supported an extended history of the utilization of lanthanum compounds for phosphate binding but with a potential to significantly enhance simple dosing and thereby improve patient adherence. Renazorb is a US-based company that's a non-aluminum, non-calcium, phosphate binder manufactured employing a patent-protected nanotechnology process. Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Akebia Therapeutics, Inc, Vifor Pharma Management Ltd., Lupin Limited, Ardelyx, Inc, Unicycive Therapeutics Inc, Keryx Biopharmaceuticals, Zeria Pharmaceutical, Fresenius Medical Care, Shire, Ultragenyx Pharmaceutical, Inc, Sun Pharmaceutical Industries, Ltd, Akebia Therapeutics Inc, and AMAG Pharmaceuticals, Inc. North America was the largest region in the hyperphosphatemia treatment market in 2021. Asia-Pacific is expected to be the fastest-growing region in the global hyperphosphatemia treatment market during the forecast period. The regions covered in the global hyperphosphatemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the global hyperphosphatemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global hyperphosphatemia treatment market is segmented - 1) By Product: Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Others 2) By Distribution channel: Hospital Pharmacy, Retail Pharmacy, Online Stores

The anti-hypertensive drugs market consists of sales of anti-hypertensive drugs and related services. These drugs are re used to prevent heart failure, kidney failure and acute stroke induced by hypertension. Some of the major anti-hypertensive drugs include diuretics, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor antagonists. The main therapeutics of anti-hypertensive drugs are diuretics, angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, beta blockers, alpha blockers, calcium channel blockers, renin inhibitors and vasodilators. Diuretics, also known as water pills, are medications that increase the amount of water and salt excreted by the body in the form of urine. The various source of diseases includes primary hypertension and secondary hypertension that are treated in hospitals, clinics and homecare. The global anti-hypertensive drugs market size is expected to grow from $35.61 billion in 2021 to $37.47 billion in 2022 at a compound annual growth rate (CAGR) of 5.2%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global anti-hypertensive drug market size is expected to reach $42.85 billion in 2026 at a CAGR of 3.4%. Sedentary lifestyle is a major driver for the growth of the anti-hypertensive drugs market. Consumption of junk food, lack of proper healthy and balanced diet, lack of proper sleep due to irregular work shifts have contributed to the increase in hypertension. Hypertension is the underlying factor for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Once the patient is diagnosed of hypertension, patients are required to use the drugs to control hypertension based on the severity of the condition. This creates a sustainable demand for the product and acts as a prominent driver for the growth of the market. Low awareness of the antihypertensive drugs amongst the population is one of the major restraints in the anti-hypertensive drugs market. Firstly, most of the people in developing nations neglect their health-check-ups and are not aware about the existing hypertension condition in them until they detect extreme symptoms. Secondly, persons diagnosed with hypertension are not adherent to their medication schedule and stop taking medication after 1-2 weeks until symptoms return, thereby posing a huge challenge to the anti-hypertensive drugs market. For example, BMC Research notes published a research survey (from a developing country) which states that out of the total 112 hypertensive subjects with stroke, only 17% of them were adherent to antihypertensive medications. Lack of awareness and low drug adherence restraint the growth of antihypertensive market. Of late, there has been rise in use of combination therapies compared to monotherapy treatment. Monotherapy is the treatment of a hypertension with a single drug, while the use of combinations of drugs (Combination Therapy) allows for action on several different hypertensive mechanisms. When the two drugs are combined with different mechanisms of action, the effect is two to five times greater than monotherapy. Increasing the dose of monotherapy reduces coronary events by 29% and cerebrovascular events by 40%, while combining two antihypertensive agents with a different mechanism of action reduces coronary events by 40% and cerebrovascular events by 54%. Thus, the use of combination therapy provides greater protection to a target organ than increasing the dose of monotherapy. The trend of using combination therapy is thus more effective and is being widely accepted as well. The US Food and Drug Administration (FDA) issued a guidance on developing fixed-combination drugs to treat hypertension. This primarily focuses on the clinical development of two-drug combinations of previously approved products. US FDA expects to see a reduction in adverse effects for combinations that include doses below each drugs’ maximum dose compared to single drug regimens at their maximum dose. Earlier physicians typically started a patient on a single drug and titrated up to a maximum dose before adding additional drugs to their program, current guidelines recommend starting patients on two drugs at less than their full doses. Hence, this guidance would keep a check on the fixed-combination drugs. Major players in the anti-hypertensive drugs market are Merck & Co. Inc., Astra Zeneca Plc, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd., Pfizer Inc., Novartis AG, Sanofi SA, United Therapeutics, Ranbaxy Laboratories, Bayer AG, Lupin Limited, Boehringer Engelheim GmbH, Sun Pharmaceuticals LLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Roche, Abbott, Gilead, Actelion, and Teva Pharmaceutical Industries Ltd. North America was the largest region in the anti-hypertensive drugs market in 2021. The Middle East is expected to be the fastest growing region in the global anti-hypertensive medication market during the forecast period. The regions covered in the global anti-hypertensive drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anti-hypertensive drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global anti-hypertensive drugs market is segmented - 1) By Therapeutic: Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators 2) By Disease Source: Primary Hypertension, Secondary Hypertension 3) By End-User: Hospitals, Clinics, Homecare

The acne drugs market consists of sales of prescription acne drugs (Salicylic acid, Retin-A Micro, Onexton, and Solodyn) and related OTC non-prescription products (cleansers, lotions, gels, toners, masks and pads containing acne drugs-fighting ingredients) which are used to treat skin diseases such as acne drugs vulgaris and acne drugs rosacea. Market in this report does not include the sales of drugs used for dermatitis and psoriasis. The global acne drugs market size is expected to grow from $5.03 billion in 2021 to $5.36 billion in 2022 at a compound annual growth rate (CAGR) of 6.7%.The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global acne drug market is expected to reach $6.55 billion in 2026 at a CAGR of 5.2%. An increase in the disposable income of people is one of the major drivers in the acne drugs market. An increase in the disposable income is usually due to an improved economy leading to increased wages and salaries boosting healthcare expenditure. According to the Office For National Statistics (UK), in 2020, the average household disposable income in UK was £30,800 ($37,830), an increase of 2.3% from 2019. Rise in disposable income increased expenditure on facial care products is expected to continue, thereby driving the market in the forecast period. Acne is a major problem worldwide; close to 90% of people suffer from some sort of acne. In America alone, close to 12 million people suffer from a severe acne problem, that can lead to scarring of the skin if left untreated, as a result many people purchase acne care drugs and products. The presence of alternatives for acne treatment is one of the restraints on the acne drugs market. Due to availability of multiple alternatives, patients tend to choose one amongst many options on the basis of price, side effects, duration and many more. This increases the competition and hence, the competition cuts down a significant portion of business for the acne drugs market. For example, some of the alternatives for the acne drugs treatment apart from acne drugs are Ayurveda, home remedy, laser and photodynamic therapy and extraction of whiteheads and blackheads using special tools like needles and forceps. Combination therapy is the latest trend in the acne drugs market. Combination therapy is the process of combining two drugs with different mechanisms of action, such combinations of medication have a better efficacy and adherence when compared with monotherapy (the use of only a single drug by itself). The combination of a topical retinoid drug, which unclogs the pores, along with an antimicrobial drug, which is used to treat an infection is being used to treat acne drugs. Example of combination therapy includes: Epiduo, Acanya, Ziana and Benzamycin produced by Galderma, Allergan, Medicis and Atrix respectively. The stringent regulations concerning the usage of drugs to treat acne has an impact on the acne drugs market. The regulations have become stringent due to the various side-effects and adverse events caused during the course of treatment. In India, the Central Drugs Standard Control Organization (CDSCO) has issued a warning regarding the safety guidelines concerning the use of the oral drug, Isotretinoin. The CDSCO has directed the State and Union Territories’ drugs controllers to check the labeling of Isotretinoin drug and make the end users aware of the serious birth defects the drug may cause. Further, the Subject Expert Committee (SEC) for Dermatology and Allergy has recommended that the drug should be sold only on the prescription of a dermatologist, manufacturers should provide a package insert in local languages and the retail chemists should maintain the details of retail sale of the drug. Hence, these strict guidelines and regulations would impact the growth of acne drugs market. In March 2019, Allergan acquired Envy Medical Inc. at an undisclosed price. This deal will help Allergan reinforce their goal towards providing customers with enhanced skin care solutions. Envy Medical's technology used in skin resurfacing procedures like Dermalinfusion, which is a non-surgical, non-invasive skin resurfacing system will immensely help Allergan gain a strong presence in the acne drugs market. Allergan plc is a pharmaceutical company established in 1948 and headquartered in Dublin, Ireland. Major players in the acne drugs market are Allergan plc, Galderma S.A., Valeant Pharmaceutical International Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., GlaxoSmithKline Plc., Bayer AG, Stiefel Laboratories Inc., Ranbaxy Laboratories Limited, Pfizer Inc., Sun Pharmaceutical Industries Limited, Mayne Pharma Group Limited, Mylan N.V., Cipher, Daiichi Sankyo Company, Ltd, Guthy-Renker LLC, Medicis Pharmaceutical Corporation, Foamix Pharmaceuticals, BioPharmX, In, Roche Holding AG, F. Hoffmann-la Roche Ltd, Anterios Inc., AndroScience, Oculus Innovative Sciences, Aqua Pharmaceuticals, Skinvisible Pharmaceuticals and Prestium Pharma Inc. North America was the largest region in the acne drugs market in 2021. The Middle East is expected to be the fastest growing region in the global acne market during the forecast period. The regions covered in the global acne medication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acne drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global acne drugs market is segmented - 1) By Type: Inflammatory Acne Drugs, Non-Inflammatory Acne Drugs 2) By End-User: Hospitals and Clinics, Pharmacies and Drug Stores, Ambulatory Surgical Centres 3) By Therapeutic Class: Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide

The dermatitis market consists of sales of dermatitis drugs such as corticosteroids, calcineurin inhibitors, PDE4 inhibitors which are used to cure inflammation of the outer layer of the body, characterized by itchy rashes on swollen and reddened skin. Some of the major dermatitis drugs include Triamcinolone, Clobetasol, Betamethasone, Hydrocortisone, Fluocinonide and Clobex. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex, and also synthetic equivalents of these hormones. The different routes of administrations include topical, oral, injectable and is used in cancer, blood disorders, chronic diseases, infectious diseases. It is distributed through various channels such as hospital, retail pharmacies, drug stores, online or mail pharmacies The global dermatitis market size is expected to grow from $5.92 billion in 2021 to $6.37 billion in 2022 at a compound annual growth rate (CAGR) of 7.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global dermatitis market is expected to reach $8.06 billion in 2026 at a CAGR of 6.1%. Growth in atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. Prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. The strict government regulations are one of the restraints for the dermatitis drug market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). In order to find the efficacy and efficiency of drug, it has to be tried on the every type of patients. The effects of certain drugs in adults are quite different than in children, as a reason result of the clinical trial cannot be used for the production of drug that will be served to the children. This hinders the research and requires more efforts in clearing regulation set by FDA. For example, as the patient population is largely children, FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation is in compliance with Children’s Health Act of 2000 that requires all the children subjected to clinical trial be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolio and improve market presence. Companies are also strategically making M&As with a view to reduce competition and increase the scalability of their business. For example, Stiefel Laboratories has been able to successfully widen its global reach after it was acquired by Glaxo Smith Kline. Also Biofrontera, Inc., a specialist in dermatology market acquired Cutanea Life Sciences, Inc.in 2019 for $7.3 million to increase their capital base and scale the business. The dermatitis drugs market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) that carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products with an aim to ensure safety, quality and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes makes the drugs more effective and safe, thereby having a positive impact on the dermatitis drugs market. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan Plc. (Republic of Ireland) and Bristol-Myers Squibb. North America is the largest region in the dermatitis market in 2021. The Middle East is expected to be the fastest growing region in the global dermatitis market during the forecast period. The regions covered in the global dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online or Mail Pharmacies 3) By Route of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases